Earnings Call · Q4 FY2022·2023-03-06

Q4 22EPS -41.67%·Rev n/aQ3 22EPS +78.26%·Rev n/aQ2 22EPS +42.86%·Rev n/aQ1 22EPS +64.52%·Rev n/a⚠ consensus missing

Anika Therapeutics, Inc. ANIK

Mark Namaroff — Investor Relations

Cheryl Blanchard — Chief Executive Officer

Mike Levitz — Chief Financial Officer

−8.6%1d on move date−8.7% vs SPY3d−14.1%5d−17.4%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ANIK calls or request research access.

More ANIK calls Browse calls Request research access